Precision oncology

Ix Therapeutics is a biotech company in the field of oncology focusing on the development of functional antibodies based on novel and proprietary targets.

Founded by Indivumed in 2021 and funded by Xlife Sciences, the joint venture strives to thereby support biopharmaceutical companies in the subsequent clinical development of medical products.

We draw on more than 20 years of experience in standardized, high-quality global sample collection and groundbreaking bioinformatics technologies.
Utilizing Indivumed’s proprietary database IndivuType and the cutting-edge analytical capabilities, we aim to make target discovery and development of diagnostic or therapeutic methods in the field of oncology faster, more reliable, and more efficient.